Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838576 | 0.84 | ATM (0.33) | SLC6A2SLC6A4SLC6A3ATM | |
| SCHEMBL2835011 | 0.81 | NPC1 (0.36) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2838035 | 0.81 | NPC1 (0.36) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL10512635 | 0.80 | NPC1 (0.35) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11212564 | 0.74 | SLC6A2 (0.54) | DRD2DRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11050238 | 0.73 | NPC1 (0.68) | NPC1RAB9ADRD2DRD1SLC6A2 | |
| Hydrochloric Acid SCHEMBL11216338 | 0.73 | SLC6A4 (0.55) | NPC1RAB9ADRD2DRD1SLC6A2 | |
| Hydrochloric Acid SCHEMBL11216803 | 0.73 | SLC6A2 (0.52) | DRD2DRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22461443 | 0.73 | DRD1 (0.48) | DRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11215925 | 0.73 | SLC6A2 (0.56) | NPC1RAB9ADRD2DRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | NPC1 1665/4885RAB9A 1933/4885DRD2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.